Apolipoprotein E Is Required for Cell Proliferation and Survival in Ovarian Cancer

Author:

Chen Yu-Chi1,Pohl Gudrun1,Wang Tian-Li2,Morin Patrice J.3,Risberg Björn4,Kristensen Gunnar B.5,Yu Albert1,Davidson Ben4,Shih Ie-Ming12

Affiliation:

1. 1Pathology, Departments of

2. 2Gynecology and Oncology, Johns Hopkins University Medical Institutions; and

3. 3National Institute of Aging, Baltimore, Maryland and Departments of

4. 4Pathology and

5. 5Gynecologic Oncology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway

Abstract

Abstract Apolipoprotein E (ApoE) has been recently identified as a potential tumor-associated marker in ovarian cancer by serial analysis of gene expression. ApoE has long been known to play a key role in lipid transport, and its specific isoforms may participate in atherosclerogenesis. However, its role in human cancer is not known. In this study, apoE expression was frequently detected in ovarian serous carcinomas, the most common and lethal type of ovarian cancer. It was not detected in serous borderline tumors and normal ovarian surface epithelium. Inhibition of apoE expression using an apoE-specific siRNA led to G2 cell cycle arrest and apoptosis in an apoE-expressing ovarian cancer cell line, OVCAR3, but not in apoE-negative cell lines. Furthermore, the phenotype of apoE siRNA–treated OVCAR3 cells was reversed by expressing engineered mutant apoE with introduced silent mutations in the siRNA target sequence. Expression of apoE in nuclei was significantly associated with a better survival in patients who presented peritoneal effusion at the time of diagnosis (5-year follow-up, P = 0.004). This study suggests a new role of apoE in cancer as apoE expression is important for the proliferation and survival in apoE-expressing ovarian cancer cells.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Reference42 articles.

1. Diamandis EP. Tumor markers: past, present and future. In: Diamandis EP, editor. Tumor markers. 1st ed. Washington (DC): American Association for Clinical Chemistry; 2002. p. 3–8.

2. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002; 48: 1198–205.

3. Shih I-M, Sokoll LJ, Chan DW. Tumor markers in ovarian cancer. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers physiology, pathobiology, technology and clinical applications. Philadelphia: AACC Press; 2002. p. 239–52.

4. Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science 1995; 270: 484–7.

5. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387–8.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3